Rigosertib sodium manufacturers
|
| | Rigosertib sodium Basic information |
| Product Name: | Rigosertib sodium | | Synonyms: | Glycine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]-, sodiuM Slat;RIGOSERTIB SODIUM;ON 01910 Na;(E)-2,4,6-Trimethoxystyryl 3-[(carboxymethyl)amino]-4-methoxybenzyl sulfone sodium salt;Novonex;ON 01910 sodium;RIGOSERTIB SODIUM (ON-01910 SODIUM);Rigosertib sodium（E） | | CAS: | 592542-60-4 | | MF: | C21H24NNaO8S | | MW: | 473.47193 | | EINECS: | | | Product Categories: | Antineoplastic protein Kinase inhibitors | | Mol File: | 592542-60-4.mol |  |
| | Rigosertib sodium Chemical Properties |
| Melting point | 174-178℃ | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Powder |
| | Rigosertib sodium Usage And Synthesis |
| Definition | ChEBI: Rigosertib sodium is the sodium salt of rigosertib. It is an anti-cancer agent which has been granted Orphan Drug Designation by the FDA for use in patients with myelodysplastic syndromes (MDS). It has a role as a microtubule-destabilising agent, an antineoplastic agent, an EC 2.7.11.21 (polo kinase) inhibitor and an apoptosis inducer. It contains a rigosertib(1-). |
| | Rigosertib sodium Preparation Products And Raw materials |
|